Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • RINVOQ Logo

      RINVOQ.com.au
      for patients

      Refer your patients to a trusted source that has useful information they need about their treatment.

      Access here

      Access Code: ASPIRE

      An information resource for Australian residents who have been prescribed RINVOQ for an approved indication.

      This website gives patients access to:

      RINVOQ information and FAQs

      Wellbeing tips

      Disease information

      Useful links

      RINVOQ Patient Alert Card
      RINVOQ Patient Alert Card

      Patient website information card

      Share this card with your patients prescribed RINVOQ to give them access to rinvoq.com.au.

      Share now →

      The information provided on rinvoq.com.au has been designed for patients prescribed RINVOQ for an approved indication and is not intended to replace advice provided by a healthcare professional.

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      RINVOQ PI

      AU-ABBV-200039. July 2023